Skip to main content

Peer Review reports

From: The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen

Original Submission
4 Nov 2013 Submitted Original manuscript
7 Nov 2013 Author responded Author comments - Emily Henderson
Resubmission - Version 2
7 Nov 2013 Submitted Manuscript version 2
11 Nov 2013 Editorially accepted
3 Dec 2013 Article published 10.1186/1471-2377-13-188

You can find further information about peer review here.

Back to article page